1. Home
  2. AG vs BEAM Comparison

AG vs BEAM Comparison

Compare AG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Majestic Silver Corp. (Canada)

AG

First Majestic Silver Corp. (Canada)

HOLD

Current Price

$17.21

Market Cap

8.2B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$28.05

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AG
BEAM
Founded
1979
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AG
BEAM
Price
$17.21
$28.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$14.25
$48.09
AVG Volume (30 Days)
20.9M
1.8M
Earning Date
11-05-2025
11-04-2025
Dividend Yield
0.12%
N/A
EPS Growth
N/A
N/A
EPS
0.16
N/A
Revenue
$965,571,000.00
$55,701,000.00
Revenue This Year
$107.63
N/A
Revenue Next Year
$18.81
$26.52
P/E Ratio
$109.98
N/A
Revenue Growth
83.84
N/A
52 Week Low
$5.09
$13.53
52 Week High
$17.91
$35.25

Technical Indicators

Market Signals
Indicator
AG
BEAM
Relative Strength Index (RSI) 66.20 60.74
Support Level $16.03 $26.17
Resistance Level $17.91 $28.64
Average True Range (ATR) 0.94 1.39
MACD 0.08 0.08
Stochastic Oscillator 80.50 78.14

Price Performance

Historical Comparison
AG
BEAM

About AG First Majestic Silver Corp. (Canada)

First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: